ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparative Study of the Efficacy and Safety of BCD-131 and Mircera in Treatment of Anemia in CKD Patients on Dialysis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03519243
Recruitment Status : Active, not recruiting
First Posted : May 8, 2018
Last Update Posted : October 9, 2018
Sponsor:
Information provided by (Responsible Party):
Biocad

Brief Summary:
BCD-131 is pegylated darbepoetin beta. BCD-131-2 is International Multicenter Randomized Open-Label Comparative Study (Phase II) of the Efficacy and Safety of BCD-131 and Mircera in Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis.

Condition or disease Intervention/treatment Phase
Anemia Biological: BCD-131 Biological: Mircera Phase 2

Detailed Description:

The hypothesis of the study is that the efficacy of BCD-131 is equivalent to that of Mircera® based on the analysis of the primary endpoint (changes in the Hb level over the period of evaluation as compared to the baseline Hb level ) during the 21-week period of treatment.

This study is a study of the maintenance treatment of anemia. The study will include up to 100 dialysis patients with stage 5D chronic kidney disease, established efficacy of dialysis and renal anemia without other causes of anemia, receiving erythropoiesis-stimulating agents (ESA) and reaching target hemoglobin levels.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Open-Label Comparative Study of the Efficacy and Safety of BCD-131 (JSC BIOCAD, Russia) and Mircera (F. Hoffmann-La Roche Ltd, Switzerland) in Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis
Actual Study Start Date : October 24, 2017
Estimated Primary Completion Date : May 1, 2021
Estimated Study Completion Date : May 1, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anemia

Arm Intervention/treatment
Experimental: BCD-131 1,05 mcg/kg * conversion ratio
subcutaneously monthly
Biological: BCD-131
subcutaneously monthly
Other Name: pegylated darbepoetin beta

Experimental: BCD-131 1,7 mcg/kg * conversion ratio
subcutaneously monthly
Biological: BCD-131
subcutaneously monthly
Other Name: pegylated darbepoetin beta

Experimental: BCD-131 2,75 mcg/kg * conversion ratio
Subcutaneously monthly
Biological: BCD-131
subcutaneously monthly
Other Name: pegylated darbepoetin beta

Active Comparator: Mircera
subcutaneously monthly
Biological: Mircera
subcutaneously monthly
Other Name: Methoxy polyethylene glycol-epoetin beta




Primary Outcome Measures :
  1. Change in Hemoglobin (Hb) Concentration From Baseline to the Evaluation Period [ Time Frame: Baseline - measurements on Screening (weeks -4 - 0) and on day 1; Evaluation period - weekly measures on weeks 21 to 23 ]
    The baseline hemoglobin will be calculated as the arithmetic mean of hemoglobin values obtained at screening and at Visit 1. The final hemoglobin value during the evaluation period will be calculated as the arithmetic mean of hemoglobin values obtained at Week 21 and Week 23.


Secondary Outcome Measures :
  1. The proportion of patients who developed AEs/SAEs that, in the Investigator's opinion, are related to BCD-131 [ Time Frame: Week 23 ]

    The proportion of patients, in each group, who developed СТСАЕ v. 4.03 Grade 3-4 AEs that, in the Investigator's opinion, are related to BCD-131

    - the proportion of patients, in each group, who discontinued the study due to AEs/SAEs


  2. The proportion of BAb- and NAb-positive patients [ Time Frame: Week 9, 23 ]

    Blood sampling for immunogenicity assessment (BAbs and NAbs) will be performed in all the patients included in the study before the first injection and then at Week 9 and Week 23.

    The immunogenicity endpoints will be analyzed after the completion of all periods of the study.


  3. AUC(0-672 hour) [ Time Frame: day 28 ]
    Area under the concentration curve from the moment of injection to 672 h [28 days])

  4. AUC(0-∞) [ Time Frame: day 28, weeks 5, 9, 13, 17, 21 ]
    Area under the concentration curve from the moment of injection to infinity

  5. Cmax [ Time Frame: day 28, weeks 5, 9, 13, 17, 21 ]
    Maximum serum concentration of the drug product) after the first injection of the test/reference drug

  6. AUEC(0-672 hour) [ Time Frame: day 28 ]
    Area under the effect curve from the drug injection to 672 h [28 days]) based on the change in the absolute reticulocyte count after the first injection of the test/reference drug

  7. AC-Emax [ Time Frame: day 28 ]
    Maximum absolute reticulocyte count after the first injection of BCD-131/Mircera®



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed written informed consent.
  • Men and women aged from 18 to 75 years (inclusive) on the day of signing informed consent;
  • End-stage kidney disease.
  • Need for dialysis for at least 3 months before signing informed consent.
  • Need for at least 12 hours on standard dialysis procedure weekly.
  • rHuEpo (epoetin alpha, epoetin beta, darbepoetin alpha) administration for at least 3 months before signing informed consent.
  • Regular rHuEpo (epoetin alfa, epoetin beta, darbepoetin alfa) administration 1, 2 or 3 times a week (stable dose, stable frequency) before signing informed consent.
  • Target hemoglobin level (100-120 g/l) for at least 3 months before signing informed consent.
  • Effective dialysis dose index (Kt/v) ≥1.2 for patients receiving hemodialysis and (Kt/v) ≥1.7 for patients receiving peritoneal dialysis.
  • TSAT ≥20%, Serum ferritin >200 ng/ml.
  • Patients and their sexual partners with childbearing potential must implement reliable contraceptive measures during all the study treatment, starting 4 weeks prior to the administration of the first dose of investigational product until 4 weeks after the last dose of investigational product. This requirement does not apply to participants who have undergone surgical sterilization. Reliable contraceptive measures include two methods of contraception, including one barrier method/
  • Patients should be able to follow the Protocol procedures

Exclusion Criteria:

  • Any other causes of anemia except for renal anemia, including folate and B12 deficiency, chronic blood loss, aluminium intoxication, sickle-cell anemia, chronic disease anemia (CRP above 20 mg/l), refractory anemia with blast cells in peripheral blood.
  • Lupus nephritis of kidney disease due to systemic vasculitis.
  • Platelet count below 100х10^9 cells/l.
  • Scheduled kidney transplant during study participation period.
  • Hypersensitivity to darbepoetin alfa or of any components of study drugs, or to Fe (III)-hydroxide-sucrose complex.
  • Vaccination less than 8 weeks before signing informed consent.
  • Liver cirrhosis with portal hypertension and/or splenomegaly and/or ascitis.
  • HIV infection, active HBV, HCV.
  • ALT, AST level above 3x ULN.
  • Congestive heart failure (Grade IV NYHA)
  • Resistant arterial hypertension.
  • Unstable angina.
  • Hemoglobinopathy, MDS, hematologic malignancy, PRCA.
  • Severe secondary hyperparathyroidism.
  • Gastrointestinal bleeding history.
  • Thrombotic events history (myocardial infarction, stroke, TIA, DVT, PATE) less than 6 months before signing informed consent.
  • Seizures, including epilepsy.
  • Major surgery in less than 1 month before signing informed consent
  • Blood transfusions in less than 3 months before signing informed consent.
  • Acute inflammatory diseases or exacerbations of chronic inflammation.
  • Severe psychiatric disorders and suicidal ideation and suicidal behavior.
  • History of malignancy, excluding appropriately treated basal cell carcinoma or cervical carcinoma in situ.
  • Alcohol or drug abuse.
  • Simultaneous participation in other trials or in less than 3 months before signing informed consent
  • Pregnancy of breast-feeding.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03519243


Locations
Belarus
City Clinical Hospital №9
Minsk, Belarus
Russian Federation
City Mariin Hospital
St. Petersburg, Russian Federation, 194104
B.Braun Avitum Russland Clinics Ltd.
St.Petersburg, Russian Federation
Sponsors and Collaborators
Biocad
Investigators
Study Chair: Roman Ivanov, PhD JCS BIOCAD
  Study Documents (Full-Text)

Documents provided by Biocad:
Statistical Analysis Plan  [PDF] June 15, 2017
Study Protocol  [PDF] June 15, 2017


Responsible Party: Biocad
ClinicalTrials.gov Identifier: NCT03519243     History of Changes
Other Study ID Numbers: BCD-131-2
First Posted: May 8, 2018    Key Record Dates
Last Update Posted: October 9, 2018
Last Verified: October 2018

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Anemia
Hematologic Diseases